| 0 (0%) | 12-26 20:16 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 288.37 | 1-year : | 336.82 |
| Resists | First : | 246.89 | Second : | 288.37 |
| Pivot price | 232.9 |
|||
| Supports | First : | 230.27  |
Second : | 220 |
| MAs | MA(5) : | 234.44 |
MA(20) : | 234.17 |
| MA(100) : | 191 |
MA(250) : | 0 | |
| MACD | MACD : | 4.4 |
Signal : | 5.7 |
| %K %D | K(14,3) : | 52 |
D(3) : | 52 |
| RSI | RSI(14): 58.7 |
|||
| 52-week | High : | 246.89 | Low : | 125.37 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NTRA ] has closed below upper band by 45.8%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 236.68 - 237.87 | 237.87 - 238.85 |
| Low: | 230.58 - 231.85 | 231.85 - 232.9 |
| Close: | 231.89 - 233.87 | 233.87 - 235.5 |
Tue, 23 Dec 2025
3 Reasons We’re Fans of Natera (NTRA) - TradingView — Track All Markets
Mon, 22 Dec 2025
J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum - Insider Monkey
Mon, 22 Dec 2025
Canaccord Genuity Maintains Natera (NTRA) Buy Recommendation - Nasdaq
Mon, 22 Dec 2025
Natera (NTRA): Revisiting Valuation After New JAMA Oncology Data on Signatera’s Colorectal Cancer Benefit - simplywall.st
Mon, 22 Dec 2025
NTRA: Canaccord Genuity Raises Price Target to $285, Maintains B - GuruFocus
Mon, 22 Dec 2025
Natera (NASDAQ:NTRA) Price Target Raised to $285.00 - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 139 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 94.9 (%) |
| Shares Short | 4,020 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | -2.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.1 |
| Profit Margin | -14.7 % |
| Operating Margin | -16.5 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -29.1 % |
| Qtrly Rev. Growth | 34.7 % |
| Gross Profit (p.s.) | 9.68 |
| Sales Per Share | 15.2 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 194 (M) |
| Levered Free Cash Flow | 181 (M) |
| PE Ratio | -101.63 |
| PEG Ratio | 0 |
| Price to Book value | 25.68 |
| Price to Sales | 15.37 |
| Price to Cash Flow | 167.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|